A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

MLA

Schroeder, Mark A., et al. “A Phase 1 Trial of Itacitinib, a Selective JAK1 Inhibitor, in Patients with Acute Graft-versus-Host Disease.” Blood Advances, vol. 4, no. 8, Apr. 2020, pp. 1656–69. EBSCOhost, https://doi.org/10.1182/bloodadvances.2019001043.

APA

Schroeder, M. A., Khoury, H. J., Jagasia, M., Ali, H., Schiller, G. J., Staser, K., Choi, J., Gehrs, L., Arbushites, M. C., Yan, Y., Langmuir, P., Srinivas, N., Pratta, M., Perales, M.-A., Chen, Y.-B., Meyers, G., & DiPersio, J. F. (2020). A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Advances, 4(8), 1656–1669. https://doi.org/10.1182/bloodadvances.2019001043

Chicago

Schroeder, Mark A., H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, et al. 2020. “A Phase 1 Trial of Itacitinib, a Selective JAK1 Inhibitor, in Patients with Acute Graft-versus-Host Disease.” Blood Advances 4 (8): 1656–69. doi:10.1182/bloodadvances.2019001043.